ProCE Banner Activity

My Take on Selecting Therapy for Patients With Mantle Cell Lymphoma

Clinical Thought
Mantle cell lymphoma is one of the most challenging lymphomas to manage. In this commentary, I share how I incorporate disease characteristics and patient preferences to select therapy in the frontline setting and beyond.

Released: July 29, 2021

Expiration: July 28, 2022

Share

Faculty

John P. Leonard

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Pharmacyclics AbbVie Company Janssen Biotech admin Janssen Sci

Faculty Disclosure

Primary Author

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

John P. Leonard, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Epizyme, Genentech/Roche, GenMab, Gilead Sciences/Kite, Incyte, Janssen, Karyopharm, MEI Pharma, Regeneron, Sutro, and Miltenyi and funds for research support from Genentech.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.